CN105358151B - 用于治疗脊髓性肌萎缩的化合物 - Google Patents
用于治疗脊髓性肌萎缩的化合物 Download PDFInfo
- Publication number
- CN105358151B CN105358151B CN201480035676.2A CN201480035676A CN105358151B CN 105358151 B CN105358151 B CN 105358151B CN 201480035676 A CN201480035676 A CN 201480035676A CN 105358151 B CN105358151 B CN 105358151B
- Authority
- CN
- China
- Prior art keywords
- base
- fluoro
- pyridine
- methylimidazole
- niacinamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13173487.3 | 2013-06-25 | ||
| EP13173487 | 2013-06-25 | ||
| PCT/US2014/043577 WO2014209841A2 (en) | 2013-06-25 | 2014-06-23 | Compounds for treating spinal muscular atrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105358151A CN105358151A (zh) | 2016-02-24 |
| CN105358151B true CN105358151B (zh) | 2019-04-12 |
Family
ID=48669815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480035676.2A Active CN105358151B (zh) | 2013-06-25 | 2014-06-23 | 用于治疗脊髓性肌萎缩的化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160145270A1 (https=) |
| EP (1) | EP3013345B1 (https=) |
| JP (1) | JP6492071B2 (https=) |
| KR (1) | KR102314290B1 (https=) |
| CN (1) | CN105358151B (https=) |
| AR (1) | AR096684A1 (https=) |
| BR (1) | BR112015030288B1 (https=) |
| CA (1) | CA2913785C (https=) |
| MX (1) | MX363456B (https=) |
| RU (1) | RU2673542C2 (https=) |
| TW (1) | TW201542543A (https=) |
| WO (1) | WO2014209841A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3035935B1 (en) | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Compounds for use in the prophylaxis and treatment of cancer |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| RU2725979C2 (ru) * | 2014-06-25 | 2020-07-08 | Ф. Хоффманн-Ля Рош Аг | ИМИДАЗО[1,2-а]ПИРАЗИН-1-ИЛ-БЕНЗАМИДЫ ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| WO2016161572A1 (en) * | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| EP3359685B1 (en) | 2015-10-09 | 2026-01-28 | University Of Southampton | Modulation of gene expression for deregulated protein expression |
| EA036399B1 (ru) | 2015-11-12 | 2020-11-06 | Ф. Хоффманн-Ля Рош Аг | Композиции для лечения спинальной мышечной атрофии |
| WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| EA201800367A1 (ru) | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| EP3933041B1 (en) | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant retardation |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| MX2019015580A (es) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| JP7312749B2 (ja) | 2017-08-04 | 2023-07-21 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングをモジュレートする方法および組成物 |
| SG11202001590RA (en) | 2017-08-25 | 2020-03-30 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| GB2610100B (en) | 2017-10-23 | 2023-08-16 | Stoke Therapeutics Inc | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| US12060558B2 (en) | 2018-05-04 | 2024-08-13 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| CN112469707B (zh) | 2018-06-27 | 2024-06-21 | 利伯纳生物科学株式会社 | 脊髓性肌萎缩症的预防剂或治疗剂 |
| HRP20240935T1 (hr) | 2018-06-27 | 2024-11-22 | Ptc Therapeutics, Inc. | Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| EP3873893A1 (en) | 2018-11-02 | 2021-09-08 | Merck Sharp & Dohme Corp. | 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors |
| WO2020150626A1 (en) * | 2019-01-18 | 2020-07-23 | Biogen Ma Inc. | Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors |
| WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| WO2020173407A1 (en) * | 2019-02-25 | 2020-09-03 | Beijing Innocare Pharma Tech Co., Ltd. | Process for preparing 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| JP7649257B2 (ja) | 2019-05-13 | 2025-03-19 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| WO2021007378A1 (en) | 2019-07-11 | 2021-01-14 | Ptc Therapeutics, Inc. | Compounds for use in treating huntington's disease |
| CN115485025A (zh) * | 2020-02-28 | 2022-12-16 | 雷密克斯医疗公司 | 用于调节剪接的化合物和方法 |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| CA3182912A1 (en) * | 2020-05-13 | 2021-11-18 | Chdi Foundation, Inc. | Htt modulators for treating huntington's disease |
| WO2022169230A1 (ko) * | 2021-02-03 | 2022-08-11 | 단국대학교 천안캠퍼스 산학협력단 | 6-메톡시니코틴아미드를 유효성분으로 포함하는 근감소증의 예방 또는 치료용 조성물 |
| MX2024005933A (es) | 2021-11-17 | 2024-08-06 | Chdi Foundation Inc | Moduladores de htt pata tratar la enfermedad de huntington. |
| JP2024542743A (ja) * | 2021-12-03 | 2024-11-15 | アールジェンタ セラピューティクス， インコーポレイテッド | ５－ピリミジンカルボキサミド誘導体及びその使用方法 |
| WO2023196972A1 (en) * | 2022-04-08 | 2023-10-12 | John Phillip Adams | Improving brain function |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101128199A (zh) * | 2004-04-23 | 2008-02-20 | 布里斯托尔-迈尔斯斯奎布公司 | 作为激酶抑制剂的单环杂环 |
| CN101218238A (zh) * | 2005-03-21 | 2008-07-09 | S*Bio私人有限公司 | 咪唑并[1,2-a]吡啶衍生物：制备及药学应用 |
| WO2009042907A1 (en) * | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| US20090105264A1 (en) * | 2005-11-03 | 2009-04-23 | Christopher Hamblett | Substituted Nicotinamide Compounds |
| WO2009147190A1 (en) * | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| WO2009151546A2 (en) * | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2010019236A1 (en) * | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Methods for treating spinal muscular atrophy |
| WO2012142459A1 (en) * | 2011-04-14 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801526D0 (sv) * | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| US7666880B2 (en) * | 2005-03-21 | 2010-02-23 | S*Bio Pte Ltd. | Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications |
| UY32138A (es) * | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
-
2014
- 2014-06-23 CA CA2913785A patent/CA2913785C/en active Active
- 2014-06-23 JP JP2016523822A patent/JP6492071B2/ja active Active
- 2014-06-23 AR ARP140102349A patent/AR096684A1/es unknown
- 2014-06-23 RU RU2015154676A patent/RU2673542C2/ru active
- 2014-06-23 BR BR112015030288-2A patent/BR112015030288B1/pt active IP Right Grant
- 2014-06-23 CN CN201480035676.2A patent/CN105358151B/zh active Active
- 2014-06-23 EP EP14816651.5A patent/EP3013345B1/en active Active
- 2014-06-23 KR KR1020157036344A patent/KR102314290B1/ko active Active
- 2014-06-23 US US14/899,397 patent/US20160145270A1/en not_active Abandoned
- 2014-06-23 MX MX2015017345A patent/MX363456B/es unknown
- 2014-06-23 WO PCT/US2014/043577 patent/WO2014209841A2/en not_active Ceased
- 2014-06-24 TW TW103121679A patent/TW201542543A/zh unknown
-
2018
- 2018-04-09 US US15/948,444 patent/US10501482B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101128199A (zh) * | 2004-04-23 | 2008-02-20 | 布里斯托尔-迈尔斯斯奎布公司 | 作为激酶抑制剂的单环杂环 |
| CN101218238A (zh) * | 2005-03-21 | 2008-07-09 | S*Bio私人有限公司 | 咪唑并[1,2-a]吡啶衍生物：制备及药学应用 |
| US20090105264A1 (en) * | 2005-11-03 | 2009-04-23 | Christopher Hamblett | Substituted Nicotinamide Compounds |
| WO2009042907A1 (en) * | 2007-09-27 | 2009-04-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| WO2009151546A2 (en) * | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2009147190A1 (en) * | 2008-06-05 | 2009-12-10 | Glaxo Group Limited | Novel compounds |
| WO2010019236A1 (en) * | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Methods for treating spinal muscular atrophy |
| WO2012142459A1 (en) * | 2011-04-14 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105358151A (zh) | 2016-02-24 |
| US20180222925A1 (en) | 2018-08-09 |
| RU2015154676A (ru) | 2017-07-28 |
| BR112015030288B1 (pt) | 2022-10-18 |
| KR20160022312A (ko) | 2016-02-29 |
| EP3013345A4 (en) | 2016-11-30 |
| JP2016530231A (ja) | 2016-09-29 |
| US10501482B2 (en) | 2019-12-10 |
| RU2673542C2 (ru) | 2018-11-28 |
| TW201542543A (zh) | 2015-11-16 |
| KR102314290B1 (ko) | 2021-10-21 |
| WO2014209841A2 (en) | 2014-12-31 |
| RU2015154676A3 (https=) | 2018-03-15 |
| JP6492071B2 (ja) | 2019-03-27 |
| WO2014209841A3 (en) | 2015-10-29 |
| AR096684A1 (es) | 2016-01-27 |
| BR112015030288A2 (https=) | 2017-08-22 |
| EP3013345A2 (en) | 2016-05-04 |
| CA2913785A1 (en) | 2014-12-31 |
| MX363456B (es) | 2019-03-25 |
| CA2913785C (en) | 2021-08-31 |
| HK1215399A1 (zh) | 2016-08-26 |
| EP3013345B1 (en) | 2017-11-22 |
| US20160145270A1 (en) | 2016-05-26 |
| MX2015017345A (es) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105358151B (zh) | 用于治疗脊髓性肌萎缩的化合物 | |
| CN106459067B (zh) | 用于治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物 | |
| ES2833576T3 (es) | Inhibidores de glutaminasa novedosos | |
| JP5658664B2 (ja) | １，２−二置換複素環式化合物 | |
| CN101998959B (zh) | 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂 | |
| Bonnefous et al. | Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models | |
| US20120135997A1 (en) | Pharmaceutical composition comprising a lactam or benzenesulfonamide compound | |
| TW201036958A (en) | Pyridazinone compounds | |
| CN102271681A (zh) | Cxcr7调节剂 | |
| CN107531633A (zh) | 5‑芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 | |
| TW201302730A (zh) | 吡唑化合物 | |
| JP6257835B2 (ja) | 新規なトリアゾロピリミジノン又はトリアゾロピリジノン誘導体、及びこれらの用途 | |
| CN110143956B (zh) | 他克林-吡啶并噻吩类化合物及其制备方法与用途 | |
| ES2770047T3 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| KR20160068957A (ko) | Ror-gamma-t의 메틸렌 결합 퀴놀리닐 조절제 | |
| AU2022381097A1 (en) | 2-(aryl-2-yl) morpholine and deuterated derivative thereof, preparation method therefor and application thereof | |
| EP4402128A1 (en) | Ahr agonists | |
| AU2022212487A1 (en) | Pyrazoleamide derivatives | |
| Jin et al. | Design, synthesis, AML activity and molecular modeling of novel IDH2 inhibitors | |
| TWI313602B (en) | Gyrase inhibitors and uses thereof | |
| CN121895236A (zh) | 一种itk激酶选择性抑制剂及其应用 | |
| CN118215655A (zh) | Ahr激动剂 | |
| HK1215399B (zh) | 用於治療脊髓性肌萎縮的化合物 | |
| CN101084215A (zh) | 作为glyt1抑制剂的哌啶和氮杂环丁烷衍生物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1215399 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |